Concepedia

Yongcong Lv

YL

Statistics

Publications

4

Citations

77

H-Index

4

Active since

2012

Affiliations

Chinese Academy of Sciences(Current)

Shanghai Institute of Materia Medica

University of Chinese Academy of Sciences

Yongcong Lv is an author at Chinese Academy of Sciences specializing in targeted cancer therapy, cancer pharmacology, and pharmacology.

Publications per year

2012–2023

4

Publications

4

O‐Linked Triazolotriazines: Potent and Selective c‐Met Inhibitors

Fang Chen, Ying Wang, Jing Ai et al. · ChemMedChem · 2012 · 21 citations

Medicine, Medicinal Chemistry, Pharmacology +8

DW10075, a novel selective and small-molecule inhibitor of VEGFR, exhibits antitumor activities both in vitro and in vivo

Mengyuan Li, Yongcong Lv, Linjiang Tong et al. · Acta Pharmacologica Sinica · 2016 · 20 citations

Medicine, Oncology, Pharmacology +10

Preclinical and early clinical studies of a novel compound SYHA1813 that efficiently crosses the blood–brain barrier and exhibits potent activity against glioblastoma

Yingqiang Liu, Zhengsheng Zhan, Zhuang Kang et al. · Acta Pharmaceutica Sinica B · 2023 · 19 citations · Full text

Medicine, Oncology, Pharmacology +17

Discovery of a New Series of Naphthamides as Potent VEGFR-2 Kinase Inhibitors

Yongcong Lv, Mengyuan Li, Ting Liu et al. · ACS Medicinal Chemistry Letters · 2014 · 17 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

1–4 of 4